BackBetter Therapeutics Overview

Better Therapeutics Current Cash

Track Better Therapeutics's current cash ($6.6M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$6.60M
↓ 70.42% YoYΔ $-15.71M vs prior year quarter

Peer average

Loading

Better Therapeutics Current Cash History

Loading

Better Therapeutics vs. peers: Current Cash Comparison

Loading

Better Therapeutics Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Better Therapeutics (BTTX) FAQ

Better Therapeutics (BTTX) currently reports a current cash of $6.6M as of September 2023. That compares with $22M in the prior-year period — down 70.4% year over year. Use the charts on this page to explore Better Therapeutics's current cash history and peer comparisons.

Better Therapeutics's current cash decreased from $22M to $6.6M — a 70.4% year-over-year decrease (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Better Therapeutics reported $6.6M in current cash as of September 2023. That compares with $22M in the prior-year period — down 70.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $6.6M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Better Therapeutics, and consider following BTTX for alerts when major investors trade the stock.